Long term results of three anti-vascular endothelial growth factor agents in pachychoroid neovasculopathy

References

• Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina 2015;35:1–9.
   PubMed Web of Science ®Google Scholar
• Gallego-Pinazo R, Dolz-Marco R, Gómez-Ulla F, et al. Pachychoroid diseases of the macula. Medical hypothesis. Med Hypothesis Discov Innov Ophthalmol 2014;3:111–115.
   PubMedGoogle Scholar
• Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 2012;32:1829–1837.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA, Freund KB, Goldbaum M, et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology 2000;107:767–777.
   PubMed Web of Science ®Google Scholar
• Jung BJ, Kim JY, Lee JH, et al. Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci Rep 2019;9:2055.
   PubMedGoogle Scholar
• Cho HJ, Jung SH, Cho S, et al. Intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. J Ocul Pharmacol Ther 2019;35:174–181.
   PubMedGoogle Scholar
• Lai TYY, Staurenghi G, Lanzetta P, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina 2018;38:1464–1477.
   PubMed Web of Science ®Google Scholar
• Dansingani KK, Balaratnasingam C, Naysan J, et al. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 2016;36:499–516.
   PubMed Web of Science ®Google Scholar
• Dansingani KK, Balaratnasingam C, Klufas MA, et al. Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol 2015;160:1243–1254.e2.
   PubMedGoogle Scholar
• Matsumoto H, Hiroe T, Morimoto M, et al. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol 2018;62:144–150.
   PubMedGoogle Scholar
• Sato T, Kishi S, Watanabe G, et al. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina 2007;27:589–594.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Kawaguchi K, Nouchi T, et al. Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci 2010;51:2173–2176.
   PubMed Web of Science ®Google Scholar
• Spaide RF. Disease expression in nonexudative age-related macular degeneration varies with choroidal thickness. Retina 2018;38:708–716.
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Mukai R, Morimoto M, et al. Clinical characteristics of pachydrusen in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2019;257:1127–1132.
   PubMedGoogle Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009;148:43–58.e1.
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. Agreed statistics: measurement method comparison. Anesthesiology 2012;116:182–185.
   PubMed Web of Science ®Google Scholar
• Peiretti E, Caminiti G, Serra R, et al. Anti-vascular endothelial growth factor therapy versus photodynamic therapy in the treatment of choroidal neovascularization secondary to central serous chorioretinopathy. Retina 2018;38:1526–1532.
   PubMedGoogle Scholar
• Radke N, Kalamkar C, Mukherjee A, et al. Intravitreal Ziv-aflibercept in treatment of naive chronic central serous chorioretinopathy related choroidal neovascular membrane. Case Rep Ophthalmol Med 2017;2017:5036248.
   PubMedGoogle Scholar
• Cheng C-K, Chan T-Y. Rapid response to intravitreal aflibercept in neovascular age-related macular degeneration after development of tachyphylaxis to bevacizumab and ranibizumab. Taiwan J Ophthalmol 2014;4:40–44.
   Google Scholar
• Papadopoulos Z. Aflibercept: a review of its effect on the treatment of exudative age-related macular degeneration. Eur J Ophthalmol 2019;29:368–378.
   PubMedGoogle Scholar
• Terao N, Koizumi H, Kojima K, et al. Distinct aqueous humour cytokine profiles of patients with pachychoroid neovasculopathy and neovascular age-related macular degeneration. Sci Rep 2018;8:10520.
   PubMedGoogle Scholar
• Invernizzi A, Benatti E, Cozzi M, et al. Choroidal structural changes correlate with neovascular activity in neovascular age related macular degeneration. Invest Ophthalmol Vis Sci 2018;59:3836–3841.
   PubMed Web of Science ®Google Scholar
• Christoforidis JB, Briley K, Binzel K, et al. Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model. Invest Ophthalmol Vis Sci 2017;58:5636–5645.
   PubMed Web of Science ®Google Scholar
• Koizumi H, Kano M, Yamamoto A, et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology 2016;123:617–624.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Koizumi H, Yamagishi T, et al. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 2012;119:1621–1627.
   PubMed Web of Science ®Google Scholar
• Schworm B, Luft N, Keidel LF, et al. Ranibizumab non-response in pachychoroid neovasculopathy: effects of switching to aflibercept. Sci Rep 2020;10:8439.
   PubMed Web of Science ®Google Scholar
• Romdhane K, Zola M, Matet A, et al. Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularization secondary to chronic central serous chorioretinopathy. Br J Ophthalmol 2020;104:910–916.
   PubMedGoogle Scholar
• Spaide RF. Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization. Am J Ophthalmol 2015;160:6–16.
   PubMed Web of Science ®Google Scholar
• Siedlecki J, Schworm B, Priglinger SG. The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina 2019;3:1013–1015.
   PubMedGoogle Scholar
• Schworm B, Luft N, Keidel LF, et al. Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy. BMC Ophthalmol 2021;21:269.
   PubMedGoogle Scholar
• Padrón-Pérez N, Arias L, Rubio M, et al. Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Invest Ophthalmol Vis Sci 2018;59:1119–1124.
   PubMed Web of Science ®Google Scholar
• Nagai N, Suzuki M, Minami S, et al. Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Sci Rep 2019;9:11389.
   PubMedGoogle Scholar
• Shimizu Y, Miyata M, Ooto S, et al. Pachychoroid-phenotype effects on 5-year visual outcomes of anti-VEGF monotherapy in polypoidal choroidal vasculopathy. Acta Ophthalmol. 2022 Jun;100(4):e943–e949.
   Google Scholar
• Chang Y-C, Cheng C-K. Difference between pachychoroid and non-pachychoroid polypoidal choroidal vasculopathy and their response to anti-vascular endothelial growth factor therapy. Retina 2019;1:1.
   Google Scholar
• Brandl C, Helbig H, Gamulescu MA. Choroidal thickness measurements during central serous chorioretinopathy treatment. Int Ophthalmol 2014;34:7–13.
   PubMed Web of Science ®Google Scholar
• Wei WB, Xu L, Jonas JB, et al. Subfoveal choroidal thickness: the Beijing eye study. Ophthalmology 2013;120:175–180.
   PubMed Web of Science ®Google Scholar